Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026
← Back to Research Index
Compare Evaluate Matrix Half-Life
Dossier · № 107 of 110 Updated Nov 17, 2026

Klow

KLOW blend · GHK-Cu + BPC-157 + TB-500 + KPV · Glow + KPV · healing+anti-inflammatory blend

ANECDOTAL · FOUR-COMPONENT REGENERATIVE BLEND (GLOW + KPV ANTI-INFLAMMATORY)

Mechanism of action

Composite formulation layering matrikine signalling, cytoprotection, actin regulation, and NF-kB suppression: GHK-Cu (copper-peptide matrikine activating ~4,000 wound-healing / collagen-elastin genes), BPC-157 (angiogenesis via VEGFR2 + epithelial / tendon repair), TB-500 (actin sequestration + stem-cell mobilisation + anti-fibrotic), KPV (alpha-MSH-derived tripeptide inhibiting NF-kB at mucosal epithelium). Klow is essentially the Glow blend plus KPV for an inflammation-suppression arm.

Researched effects

Inflammatory tissue / mucosal repair; injury and post-surgical recovery; skin regeneration; gut-barrier support when inflammation is part of the picture; broader repair spectrum than Glow alone (adds the KPV anti-inflammatory arm)

Dosing reported in literature

Typical SC protocols deliver ~250 mcg of each component daily (per-component basis from a combined-mg vial) for 4-8 week loading cycles. Confirm vial composition with vendor before computing per-component dose

Known concerns

No human-trial data on the combined formulation; each component carries its own risk profile (TB-500 WADA-banned, theoretical pro-proliferative concerns; copper accumulation at chronic GHK-Cu doses); injection-site reactions; meaningful batch-to-batch composition variability across compounders

Continue reading